![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Clinical and virological characteristics of DAA-experienced patients with chronic
HCV infection treated with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX):
results from the Frankfurt Resistance Database
|
|
|
Reported by Jules Levin
EASL 2018 April 11-15 Paris France
Johannes Vermehren, Julia Dietz, Kai-Henrik Peiffer, Simone Susser, Stefan Zeuzem, Christoph Sarrazin
Medizinische Klinik 1, Universitätsklinikum Frankfurt, Frankfurt am Main, Germany
![0420181](../images%20/042018/042018-15/0420181.gif)
![0420182](../images%20/042018/042018-15/0420182.gif)
![0420183](../images%20/042018/042018-15/0420183.gif)
![0420184](../images%20/042018/042018-15/0420184.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|